Competition and saturation make transporter capacity a central determinant of drug exposure. When several molecules seek the same carrier, they can interfere with one another; as available carriers become occupied, increasing substrate concentration may no longer produce a proportional increase in transport. These properties help explain why coadministered compounds can alter drug concentrations and why dose-related effects may become nonlinear.
Passive and active carrier-mediated transport differ in what supplies the driving force. Passive movement follows a concentration gradient, whereas active movement is coupled either to cellular energy or to an ion gradient. This distinction matters because the relevant gradient or energy source can determine whether a molecule continues to move across a membrane as concentrations on the two sides change.
Genetic variation in transporters can change the amount of drug moved across a membrane. Because transport systems participate in absorption, tissue entry, and renal or hepatic secretion, an inherited difference may influence drug concentrations at more than one stage of disposition. The resulting variability can contribute to differences in therapeutic response or toxicity among individuals receiving the same drug.
Carrier-mediated transport is especially consequential at the intestinal epithelium, where it can influence drug entry after oral administration. It also affects movement into tissues and contributes to secretion by the kidneys and liver. Examining these locations connects membrane transport with the pharmacologic processes that determine how much drug is absorbed, where it distributes, and how it is eliminated.
To interpret a possible transporter-based drug interaction, pharmacologists consider whether two compounds depend on the same carrier and whether transport becomes limited by carrier occupancy. A competing compound may change the amount transported, which can shift drug concentrations. The relevant concern is not merely altered movement at a membrane, but possible changes in therapeutic efficacy or toxicity.
Studies of these systems can link a transport process to absorption, distribution, or elimination rather than treating drug concentration as a purely passive consequence of diffusion. Altered movement across an intestinal barrier, into tissue, or through renal and hepatic secretion can help explain concentration changes. This interpretation provides context for variable responses, interactions, efficacy, and toxicity.